Loading...
XNAS
CNSY
Market cap4mUSD
Sep 17, Last price  
2.03USD
1D
-0.49%
1Q
-51.67%
Jan 2017
-100.00%
IPO
-100.00%
Name

Plus Therapeutics Inc

Chart & performance

D1W1MN
XNAS:CNSY chart
P/E
—
P/S
0.94
EPS
—
Div yield, %
—
Shrs. gr., 5y
142.27%
Rev. gr., 5y
76.66%
Revenues
5m
-10.49%
7,927,0006,049,0006,853,00014,730,00010,627,0009,996,00014,501,00012,196,0007,598,00011,659,00011,380,0006,411,0002,983,0006,998,000303,0000224,0004,913,0005,824,0005,213,000
Net income
-22m
L+72.49%
-25,447,000-28,672,000-30,036,000-23,216,000-27,494,000-32,451,000-32,279,000-26,177,000-37,368,000-18,744,000-22,046,000-22,686,000-12,634,000-10,887,000-8,241,000-13,399,000-20,275,000-13,316,000-12,978,000-22,386,000
CFO
-21m
L+96.84%
-16,483,000-29,995,000-33,389,000-23,807,000-23,574,000-35,323,000-32,193,000-34,563,000-30,330,000-20,468,000-19,533,000-18,128,000-11,975,000-5,906,000-8,434,000-10,280,000-12,972,000-12,851,000-10,554,000-20,775,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Key people

Marc H. Hedrick
President, Chief Executive Officer, Director · since 2014
Steven Kesten
President and Chief Medical Officer · since 2018
Gregory Stein
Senior Vice President of Clinical Development · since 2020
Desiree Smith
Principal Accounting Officer, Corporate Controller · since 2020
Andrew Sims
Chief Financial Officer, Vice President - Finance · since 2020
Mark Marino
Chief Medical Officer · since 2016
Ronald Martell
Independent Director · since 2016
Annigje van Es-Johansson
Independent Director · since 2020
URL
http://www.plustherapeutics.com/
IPO date
Aug 09, 2000
Employees
17
Domiciled in
US
Incorporated in
US
Legal address
C/O National Corporate Research, Ltd.
850 New Burton Road
Suite 201
Dover, DE 19904
US
Headquarters
3020 Callan Road
San Diego, CA 92121
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT